Ultime notizie per Astellas Pharma (OTC:ALPMF) Azioni

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Biotech

Large Cap

News

Health Care

General

ALPMF

ALPMY

Nuove prospettive terapeutiche emergono da una ricerca clinica, aprendo orizzonti inattesi nella lotta contro questa aggressiva neoplasia.

Carcinoma uroteliale: studio EV-302 Pfizer/Astellas mostra progressi

ASTELLAS PHARMA INC by Astellas Pharma, Inc.

Astellas Pharma Inc

Jefferies analyst Stephen Barker maintained a Hold rating on Astellas Pharma (ALPMF – Research Report) yesterday and set a price target of Yen1,700...

Jefferies Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)

Bernstein analyst Miki Sogi maintained a Buy rating on Astellas Pharma (ALPMF – Research Report) today and set a price target of Yen2,100.00. The c...

Bernstein Remains a Buy on Astellas Pharma (ALPMF)

CMS aiming for more transparency in drug pricing negotiations

Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance

Astellas Pharma (($JP:4503)) has held its Q3 earnings call. Read on for the main highlights of the call. The latest earnings call for Astellas Phar...

Astellas Pharma's Earnings Call: Mixed Outcomes and Strategic Shifts

Astellas Pharma Non-GAAP EPS of ¥124.60, revenue of ¥1453.03B; updates FY outlook

Astellas Pharma ( ($JP:4503) ) has provided an announcement. Astellas Pharma reported extraordinary losses of JPY 60.6 billion in its non-consolida...

Comments

Astellas Pharma

Notizie

Ultime notizie per Astellas Pharma (OTC:ALPMF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO